GH Research’s (GHRS) “Market Outperform” Rating Reiterated at JMP Securities

by · The Markets Daily

JMP Securities reaffirmed their market outperform rating on shares of GH Research (NASDAQ:GHRS – Free Report) in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has a $39.00 price target on the stock.

Several other research analysts have also recently weighed in on GHRS. HC Wainwright reaffirmed a “buy” rating and set a $40.00 target price on shares of GH Research in a research note on Friday, May 9th. Royal Bank Of Canada assumed coverage on GH Research in a research note on Friday, March 7th. They set an “outperform” rating and a $31.00 target price for the company. Wall Street Zen cut GH Research from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Stifel Nicolaus raised their target price on GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Finally, Guggenheim reduced their target price on GH Research from $32.00 to $29.00 and set a “buy” rating for the company in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.00.

View Our Latest Stock Analysis on GHRS

GH Research Stock Performance

NASDAQ:GHRS opened at $12.40 on Tuesday. The business has a fifty day moving average of $11.30 and a 200-day moving average of $10.60. GH Research has a 1 year low of $6.00 and a 1 year high of $20.50. The stock has a market cap of $645.17 million, a price-to-earnings ratio of -15.70 and a beta of 0.97.

GH Research (NASDAQ:GHRS – Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.42. On average, equities research analysts predict that GH Research will post -0.8 EPS for the current year.

Institutional Investors Weigh In On GH Research

Several hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets purchased a new stake in GH Research in the 4th quarter worth about $44,000. Palumbo Wealth Management LLC purchased a new stake in GH Research in the 1st quarter worth about $142,000. XTX Topco Ltd purchased a new stake in GH Research in the 1st quarter worth about $169,000. Two Sigma Investments LP purchased a new stake in GH Research in the 4th quarter worth about $117,000. Finally, Millennium Management LLC purchased a new stake in GH Research in the 4th quarter worth about $145,000. 56.90% of the stock is owned by hedge funds and other institutional investors.

About GH Research

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Read More